Patents Examined by Patricia Duffy
  • Patent number: 10995142
    Abstract: Provided in the present invention are a monoclonal antibody FnAb8 and application thereof.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: May 4, 2021
    Assignee: Shanghai Jiaotong University
    Inventors: Yuhong Xu, Yangsheng Qiu
  • Patent number: 10988748
    Abstract: Polypeptides, and methods for their use, are disclosed that have an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:1, are provided, wherein (a) the polypeptide degrades a PFQPQLPY (SEQ ID NO: 140) peptide and/or a PFPQPQQPF (SEQ ID NO: 68) at pH 4; (b) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and (c) the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174, and 456.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: April 27, 2021
    Assignees: University of Washington, The Regents of the University of California
    Inventors: Ingrid Swanson Pultz, Clancey Wolf, Justin Bloomfield Siegel, Christine Elaine Tinberg, Lance Stewart, David Baker
  • Patent number: 10988600
    Abstract: A hyaluronic acid product is comprising a cross-linked hyaluronic acid and one or more cyclodextrin molecules, and further comprising a guest molecule capable of forming a guest-host complex with the aminocyclodextrin molecule acting as a host, wherein the guest molecule is a retinoid, preferably adapalene, or a RAM BA. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: April 27, 2021
    Assignee: GALDERMA HOLDING SA
    Inventors: Katarina Edsman, Jean-Guy Boiteau
  • Patent number: 10988511
    Abstract: Homologs of the E. coli proteins orf353, bacterial lg-like domain (group 1) protein (orf405), flu antigen 43 (orf1 364), NodT-family outer-membrane-factor-lipoprotein efflux transporter (orf1 767), gspK (orf3515), gspJ (orf3516), toriB-dependent siderophore receptor (orO597), fibrial protein (orf3613), upec-948, upec-1232. A chain precursor of the type-1 fimbria! protein (upec-1875), yapH homolog (upec-2820), hemolysin A (recp-3768), and Sel 1 repeat-containing protein (upec-521 1) from several pathogenic strains of E. coli have been identified with regions within the proteins that are conserved across all E. coli. Fragments corresponding to the conserved regions, especially immunogenic fragments such a linear B-epitopes, are provided.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: April 27, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Laura Serino, Maria Rita Fontana, Danilo Gomes Moriel
  • Patent number: 10987310
    Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: April 27, 2021
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventors: Clark Allphin, James Pfeiffer
  • Patent number: 10975155
    Abstract: Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: April 13, 2021
    Assignee: MEDIMMUNE, LLC
    Inventors: Manuel Baca, Stacey Drabic, Peter Emtage, Ronald Herbst
  • Patent number: 10973768
    Abstract: The present disclosure relates to methods for making extended-release formulations of water-soluble active pharmaceutical ingredients such as metformin HCl. In one aspect, the disclosure provides a method that includes adding an aqueous solution of an active pharmaceutical ingredient to an agitated mixture of one or more release-modifying polymers and optionally one or more binders in one or more organic solvents, the one or more organic solvents together being an antisolvent for the active pharmaceutical ingredient, water being sufficiently soluble in the one or more organic solvents such that the water added as part of the aqueous solution dissolves in the mixture, the addition thereby precipitating the active pharmaceutical ingredient; separating the active pharmaceutical ingredient and the one or more release-modifying polymers and, if present, the one or more binders from the one or more organic solvents to yield co-processed particles; and drying the co-processed particles.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: April 13, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Deniz Erdemir, Shih-Ying Chang, Divyakant Desai, San Kiang
  • Patent number: 10973915
    Abstract: Anti-PD-1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancers and autoimmune diseases.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 13, 2021
    Assignee: SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD.
    Inventors: Lile Liu, Xinxiu Yang, Haishan Luo, Hu Liu, Zhengrong Shuai, Jian Wang, Qin Zhong, Qing Duan, Hongzhuan Gu, Tatchi Teddy Yang
  • Patent number: 10973868
    Abstract: The present disclosure relates to a composition comprising a carnosine-magnesium complex. The composition is designed to be applied to the skin and causes an increase in carnosine levels in the body. The topical 5 composition comprising a carnosine-magnesium complex has the effect of improving an athlete's physical performance and may be effective for the treatment of a variety of medical conditions. Also disclosed is a method for preparing the carnosine-magnesium complex.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: April 13, 2021
    Inventors: Chad Macias, Tim Sharpe, Massimo Ferrari
  • Patent number: 10966931
    Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 6, 2021
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventors: Clark Allphin, James Pfeiffer
  • Patent number: 10967063
    Abstract: A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or more other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: April 6, 2021
    Assignee: Vyne Therapeutics Inc.
    Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
  • Patent number: 10959956
    Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: March 30, 2021
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventors: Clark Allphin, James Pfeiffer
  • Patent number: 10940211
    Abstract: The present invention provides antibodies that bind to Staphylococcus aureus Hemolysin A toxin, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Hemolysin A. The antibodies of the invention are useful for inhibiting or neutralizing Hemolysin A activity, thus providing a means of preventing or treating a Hemolysin A-related disease or disorder such as S. aureus infection. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of a S. aureus infection.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: March 9, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Alida Coppi, Peter Mason, William Olson
  • Patent number: 10925969
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize B-Cell Maturation Antigen (BCMA) are disclosed. Chimeric antigen receptors (CARs), anti-BCMA binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer and methods of treating or preventing cancer are also disclosed.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 23, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Service, Sanford Research
    Inventors: Ira H. Pastan, Tapan Bera, Satoshi Nagata, Tomoko Ise, Yasuhiro Abe
  • Patent number: 10918607
    Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: February 16, 2021
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
  • Patent number: 10912739
    Abstract: The present technology relates generally to devices for treatment of skin and skin conditions, as well as methods for preparing the devices and methods of treatment using the devices. Suitably, the devices comprise a hydrocolloid dressing and one or more active agents, wherein the amount of the active agent(s) does not reduce the absorption properties of the hydrocolloid dressing.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: February 9, 2021
    Assignee: PEACE OUT INC.
    Inventor: Enrico Frezza
  • Patent number: 10912794
    Abstract: The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: February 9, 2021
    Assignee: KEMIN INDUSTRIES, INC.
    Inventors: Geoffrey Paul Horst, Robert Bernard Levine
  • Patent number: 10875772
    Abstract: A hydrogel comprising a colloidal suspension of MIXMIIYPZ two-dimensional nanocrystals in water, wherein MI is Na+ and/or Li+, MII is Mg2+ or a mixture of Mg2+ with one or more Ni2+, Zn2+, Cu2+, Fe2+ and/or Mn2+, P is a mixture of dibasic phosphate ions (HPO42?) and tribasic phosphate ions (PO43?), X ranges from about 0.43 to about 0.63, Y ranges from about 0.10 to about 0.18, Z ranges from about 0.29 to about 0.48, X, Y, Z being mole fractions, is provided.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: December 29, 2020
    Assignee: INVICARE INC.
    Inventors: Faleh Tamimi Marino, Ashwaq Ali Al-Hashedi, Marco Laurenti, Ahmed Ebraheem Al Subaie, Mohamed-Nur Abdallah, Iskandar Tamimi Marino
  • Patent number: 10874618
    Abstract: The invention relates to a new fixed dose combination of benazepril with pimobendan.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 29, 2020
    Assignee: Elanco Tiergesundheit AG
    Inventors: Jernej Grmas, Zdenka Jerala-Strukelj, Sebastjan Reven
  • Patent number: 10870669
    Abstract: The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: December 22, 2020
    Assignee: M BIO TECHNOLOGY INC.
    Inventors: Kazuhiro Matsuda, Yuko Shingu